Add to ORKGPostoperative recurrence is the main cause of primary treatment failure in the resectable non-small cell lung cancer (NSCLC). Systematic treatments should be taken to decrease the recurrence. Adjuvant chemotherapy, including neoadjuvant chemotherapy, postoperative adjuvant chemotherapy and targeted therapy, is a widely used in this area. In this review, we summarize the clinical trials and meta-analysis related to the adjuvant chemotherapy and targeted therapy in patients with early stage NSCLC
Many randomised controlled trials have investigated the effect of adjuvant chemotherapy in operable ...
Many randomised controlled trials have investigated the effect of adjuvant chemotherapy in operable ...
Many randomised controlled trials have investigated the effect of adjuvant chemotherapy in operable ...
Lung cancer is the leading cause of death in the world. Non-small cell lung cancer (NSCLC) represent...
Despite surgical resection, patients with early-stage (I to IIIA) non–small cell lung cancer (NSCLC)...
Abstract:Despite improved surgical techniques, relapse and mortality rates remain high among patient...
Radical surgery remains the only treatment with curative potential for patients with operable non-sm...
Surgery is the primary treatment for patients with stage I, II, or IIIA non-small-cell lung cancer (...
BACKGROUND: To evaluate the effects of administering chemotherapy following surgery, or following su...
The morbidity and mortality of lung cancer rank the first place among all the malignant tumor. Accor...
Background and objective The therapeutic effect and side effect of neoadjuvant chemotherapy were sti...
The recent publication of many randomised trials about (neo)adjuvant chemotherapy in resectable non-...
Surgery remains the initial treatment for patients with early-stage non-small cell lung cancer (NSCL...
Lung cancer is the leading cause of cancer-related death worldwide. Since prognosis of early-stage n...
Many randomised controlled trials have investigated the effect of adjuvant chemotherapy in operable ...
Many randomised controlled trials have investigated the effect of adjuvant chemotherapy in operable ...
Many randomised controlled trials have investigated the effect of adjuvant chemotherapy in operable ...
Many randomised controlled trials have investigated the effect of adjuvant chemotherapy in operable ...
Lung cancer is the leading cause of death in the world. Non-small cell lung cancer (NSCLC) represent...
Despite surgical resection, patients with early-stage (I to IIIA) non–small cell lung cancer (NSCLC)...
Abstract:Despite improved surgical techniques, relapse and mortality rates remain high among patient...
Radical surgery remains the only treatment with curative potential for patients with operable non-sm...
Surgery is the primary treatment for patients with stage I, II, or IIIA non-small-cell lung cancer (...
BACKGROUND: To evaluate the effects of administering chemotherapy following surgery, or following su...
The morbidity and mortality of lung cancer rank the first place among all the malignant tumor. Accor...
Background and objective The therapeutic effect and side effect of neoadjuvant chemotherapy were sti...
The recent publication of many randomised trials about (neo)adjuvant chemotherapy in resectable non-...
Surgery remains the initial treatment for patients with early-stage non-small cell lung cancer (NSCL...
Lung cancer is the leading cause of cancer-related death worldwide. Since prognosis of early-stage n...
Many randomised controlled trials have investigated the effect of adjuvant chemotherapy in operable ...
Many randomised controlled trials have investigated the effect of adjuvant chemotherapy in operable ...
Many randomised controlled trials have investigated the effect of adjuvant chemotherapy in operable ...
Many randomised controlled trials have investigated the effect of adjuvant chemotherapy in operable ...